Antipruritic Effect of Acupuncture in Patients with Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial

Kim, YK; Yeom, M; Kang, SH; Park, HJ; Kim, K; Lee, H

Antipruritic Effect of Acupuncture in Patients with Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial

Kim, YK Yeom, M Kang, SH Park, HJ Kim, K Lee, H

Permalink

Publication Type:: Journal Article
Citation:: Evidence-based Complementary and Alternative Medicine, 2017, 2017
Issue Date:: 2017-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (1.7 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kim, YK	en_US
dc.contributor.author	Yeom, M	en_US
dc.contributor.author	Kang, SH	en_US
dc.contributor.author	Park, HJ	en_US
dc.contributor.author	Kim, K	en_US
dc.contributor.author	Lee, H https://orcid.org/0000-0002-1107-9389	en_US
dc.date.available	2017-09-27	en_US
dc.date.issued	2017-01-01	en_US
dc.identifier.citation	Evidence-based Complementary and Alternative Medicine, 2017, 2017	en_US
dc.identifier.issn	1741-427X	en_US
dc.identifier.uri	http://hdl.handle.net/10453/123579
dc.description.abstract	© 2017 Yu-Kang Kim et al. This study aims to test the feasibility of a randomised clinical trial to evaluate how acupuncture affects atopic dermatitis (AD) symptoms and quality of life and to explore potential biomarkers that may be associated with AD. It is a sham-controlled trial in which 30 eligible patients will be randomly allocated in a 1: 1: 1 ratio to one of three groups: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks); VA group 2 (twice weekly for 4 weeks); or sham acupuncture group (SA; twice weekly for 4 weeks). SA will consist of nonpenetrating acupuncture. Outcome measures will include the Visual Analogue Scale for itch, SCORing Atopic Dermatitis, and Eczema Area and Severity Index to evaluate AD symptoms improvement along with the Patient Oriented Eczema Measure and Dermatology Life Quality Index to assess quality of life. Measures will be collected at baseline, once weekly during the treatment period, and after a 4-week follow-up period. Blood collection will be at baseline and 4 and 8 weeks after treatment and compared with healthy controls. Illumina sequencing will be used to profile microRNA expression in each group to explore candidate microRNA biomarkers for specific effects of acupuncture in patients with AD. This trial is registered via US National Institutes of Health Clinical Trials registry (ClinicalTrials.gov) on 15 July 2016, identifier: NCT02844452.	en_US
dc.relation.ispartof	Evidence-based Complementary and Alternative Medicine	en_US
dc.relation.isbasedon	10.1155/2017/1926806	en_US
dc.subject.classification	Complementary & Alternative Medicine	en_US
dc.title	Antipruritic Effect of Acupuncture in Patients with Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial	en_US
dc.type	Journal Article
utslib.citation.volume	2017	en_US
utslib.for	1104 Complementary and Alternative Medicine	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	2017	en_US

Abstract:

© 2017 Yu-Kang Kim et al. This study aims to test the feasibility of a randomised clinical trial to evaluate how acupuncture affects atopic dermatitis (AD) symptoms and quality of life and to explore potential biomarkers that may be associated with AD. It is a sham-controlled trial in which 30 eligible patients will be randomly allocated in a 1: 1: 1 ratio to one of three groups: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks); VA group 2 (twice weekly for 4 weeks); or sham acupuncture group (SA; twice weekly for 4 weeks). SA will consist of nonpenetrating acupuncture. Outcome measures will include the Visual Analogue Scale for itch, SCORing Atopic Dermatitis, and Eczema Area and Severity Index to evaluate AD symptoms improvement along with the Patient Oriented Eczema Measure and Dermatology Life Quality Index to assess quality of life. Measures will be collected at baseline, once weekly during the treatment period, and after a 4-week follow-up period. Blood collection will be at baseline and 4 and 8 weeks after treatment and compared with healthy controls. Illumina sequencing will be used to profile microRNA expression in each group to explore candidate microRNA biomarkers for specific effects of acupuncture in patients with AD. This trial is registered via US National Institutes of Health Clinical Trials registry (ClinicalTrials.gov) on 15 July 2016, identifier: NCT02844452.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/123579